Although the outcomes of patients with mantle cell lymphoma (MCL) have improved, there is still no cure. Bortezomib has a 33% response rate in relapsed/refractory MCL and has shown additive and/or synergistic effects in preclinical trials with known effective agents. METHODS: This is a report of a prospective phase 2 trial of bortezomib added to rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (BzR-hyperCVAD)/rituximab, high-dose methotrexate, and high-dose cytarabine (BzR-MA) for 95 patients with newly diagnosed MCL. RESULTS: The overall and complete response rates were 100% and 82%, respectively. Hematologic toxicity was high but expected and did not lead to an increased incidence of neutropenic fever or dose reductions in comparison with a similar reported regimen without bortezomib. After a median follow-up of 44 months, the median overall survival had not been reached, and the time to treatment failure (TTF) was 55 months, which is not different from that of historical controls. CONCLUSIONS: BzR-hyperCVAD/BzR-MA at the dose and schedule studied produced high rates of response and a TTF similar to that of historical reports without bortezomib. Cancer 2018;124:2561-9.
INTRODUCTION
Despite definite improvements in the depth and duration of response, patients with mantle cell lymphoma (MCL) will relapse. 1, 2 Bortezomib achieves an overall response rate (ORR) of 33% in patients with relapsed or refractory MCL and has an acceptable toxicity profile. 3 Preclinical data suggest additive and/or synergistic effects in both in vitro and in vivo models when bortezomib is combined with cyclophosphamide, 4 doxorubicin, 5 vincristine, 5 dexamethasone, 6 cytarabine, 7, 8 and rituximab 9 in a schedule-dependent manner. 4, 8 A combination of bortezomib with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (BzR-HCVAD) alternating with bortezomib plus rituximab, high-dose methotrexate, and high-dose cytarabine (BzR-MA) is feasible. 10 
MATERIALS AND METHODS

Patient Selection
Patients with newly diagnosed MCL were enrolled into a phase 2 trial approved by the institutional review boards of both The University of Texas MD Anderson Cancer Center and John Theurer Cancer Center at Hackensack University Medical Center. Eligible patients were 18 to 79 years old, had an Eastern Cooperative Oncology Group performance status of 2 or less, 11 and had adequate organ function (a cardiac ejection fraction 50%, a normal serum bilirubin level, and a serum creatinine level < 2 mg/dL as well as an absolute neutrophil count 1000/mL and a platelet count 100,000/mL unless this was attributable to underlying lymphoma from bone marrow involvement and/or massive splenomegaly). Patients with a mantle zone histological pattern were excluded, as were those who had central nervous system involvement, had a human immunodeficiency virus 1 infection, had active hepatitis, were pregnant, had grade 2 peripheral neuropathy within 14 days of the start of the study, had a second malignancy with a 5-year survival probability < 90%, or had a hypersensitivity to boron or mannitol.
Study Design and Statistics
Descriptive statistics included means, standard deviations, medians, and ranges for continuous variables. Fisher's exact test or the chi-square test was used to assess associations between 2 categorical variables. The Wilcoxon ranksum or Kruskal-Wallis test was used to evaluate differences in continuous variables between or among patient groups. The Kaplan-Meier method was used to estimate time to treatment failure (TTF) and overall survival (OS) rates. The log-rank test was used to evaluate differences between subgroups for time-to-event endpoints. Multivariate Cox proportional hazards models were fitted to assess the effects of prognostic factors on the time-toevent outcomes. The software programs SAS 9.1.3 (SAS Institute, Cary, North Carolina) and S-Plus 8.0 (TIBCO Software, Inc, Palo Alto, California) were used for all statistical analyses.
The primary endpoint was TTF, with an event defined as a recurrence or progression of disease or death from either disease or toxicity. The hypothesis was that the addition of bortezomib would prolong the median TTF duration from 4.7 to 8.8 years. The statistical design called for the analysis to be performed no sooner than 2 years after the last patient was enrolled in the trial.
The secondary endpoint was toxicity. A Bayesian toxicity monitoring schema was used to monitor severe toxicity, which was defined per patient as 2 episodes of neutropenic fever during all therapy or of grade 3 or 4 neurologic toxicity. The trial was to be stopped early if there was a greater than 90% chance that more than 15% of patients would experience severe toxicity.
For the efficacy endpoint, an intention-to-treat analysis was applied to all eligible patients. For the toxicity endpoint, the analysis included all patients who received the treatment, regardless of their eligibility or the duration or dose of the treatment.
Pretreatment Clinical Evaluation
The pretreatment evaluation included a physical examination; chest radiography; computed tomography of the neck, chest, abdomen, and pelvis; bilateral bone marrow biopsies with unilateral aspiration; and an optional positron emission tomography/computed tomography scan. In addition, blood was drawn for a serum chemistry analysis, a complete blood count, the measurement of the serum b 2 -microglobulin level, and a flow cytometry immunophenotypic analysis of lymphocyte markers.
Toxicity Data Collection
Hematologic and nonhematologic toxicities were graded according to version 3 of the Common Terminology Criteria for Adverse Events. Blood was collected from all patients for a complete blood count with differential 2 or 3 times per week. Before each cycle of chemotherapy, a complete blood chemistry profile and a physical examination were conducted.
The response was assessed every 2 cycles according to established criteria. 12 The response assessments included computed tomography scans of the neck, chest, abdomen, and pelvis; bone marrow biopsy and aspiration; and flow cytometry analyses of peripheral blood and bone marrow samples. Colonoscopy was performed after the second or third cycle and, if positive, was repeated after the sixth cycle.
The total number of cycles was determined as in the original publication. 13 Patients who experienced complete remission (CR) after 2 to 3 cycles received a total of only 6 cycles of therapy. Patients who were not in CR after the first 2 to 3 cycles but who achieved CR after 6 cycles received 2 more alternating cycles. Patients who did not experience CR after 6 cycles were removed from the study and underwent salvage therapy with stem cell transplantation if eligible. Part A (BzR-HCVAD) was considered one cycle, and part B (BzR-MA) was considered another cycle.
Pathologic Analysis
Pathologic material was reviewed by the Department of Hematopathology at The University of Texas MD Anderson Cancer Center or Hackensack University Medical Center and was interpreted according to the World Health Organization classification of hematological and lymphoid cancers.
14 A diagnosis was based on the presence of compatible morphological and immunophenotypic findings Original Article along with the expression of cyclin D1 and/or the presence of the t(11;14)(q13;q32)/CCND1-IGH. All Ki-67 values were based on a central review at our institution.
Chemotherapy
The treatment scheme is shown in Table 1 . Doxorubicin was given as a bolus to optimize its effectiveness when it was combined with bortezomib, as reported in preclinical data. Patients who were older than 60 years or had a pretreatment serum creatinine level 2 mg/dL received cytarabine at only 1 g/m 2 per dose. The first dose of rituximab was delayed for patients with peripheral blood involvement by MCL and was administered per the clinician's discretion.
Prophylaxis for each chemotherapy course included 5 mg/kg subcutaneous granulocyte colony-stimulating factor daily starting 24-36 hrs from end of infusion of chemotherapy regimen 3 10 days or until absolute neutrophil counts recovered to >4,000/mm 3 , as well as 100 mg of oral fluconazole daily and 500 mg of oral ciprofloxacin twice a day, beginning 24 to 36 hours and for 10 days. Oral valacyclovir at 500 mg was given daily throughout chemotherapy. A 1% ophthalmic solution of prednisolone at a dose of 2 drops in each eye 4 times daily was administered; it was started on day 3 of the cytarabine-containing regimen and was continued for 7 days. Folinic acid (citrovorum factor) rescue therapy was given as previously described. Patients with evidence of third spacing/effusion did not receive the methotrexate-containing cycle until the third spacing was resolved; instead, the cycle of BzR-HCVAD was repeated.
RESULTS
Patient Characteristics
Between April 1, 2007, and December 31, 2013, 95 patients with untreated, aggressive MCL were enrolled in the study, with their clinical characteristics as shown in Table 2 . Their median age was 61 years (range, 38-75 years). Sixty patients had Ki-67 information available, and of these, 53% had a Ki-67 level 30% (range, 1%-80%). Nearly two-thirds of the patients had an intermediate/high Mantle Cell International Prognostic Index (MIPI) score, and 9% had the blastoid variant. The median Ki-67 level was 45% for patients with the blastoid variant versus 30% for patients without a blastoid cytology.
Response
One of the 95 patients who registered in the trial rescinded participation before starting treatment. Of the 94 patients who started therapy, 1 patient withdrew after cycle 1 for non-therapy-related issues, another patient was diagnosed with a second malignancy (pancreatic cancer) before the start of cycle 2 and was removed from the study, and a third patient was lost to follow-up after receiving 1 cycle of chemotherapy. In addition, 4 patients died of sepsis before the first response assessment. For the 87 patients evaluable for a response, the ORR and CR rates were 100% and 82%, respectively. Variables associated with a lower CR rate included a blastoid variant (50% vs 85%; P 5 .03) and a b 2 -microglobulin level of 3 mg/dL or higher (67.6% vs 91.1%; P 5 .01).
Survival
Ninety-four evaluable patients were included in the intent-to-treat survival analyses. At the median follow-up time of 44 months, the median OS and TTF durations for the entire population were not reached and 55 months, respectively. Variables associated with longer median TTF and OS durations included an age 65 years, a nonblastoid cytology, a b 2 -microglobulin level < 3 mg/dL, a Ki-67 level < 50%, and a low MIPI score of 0 to 3 (Table 3 and Figs. 1 and 2) . Patients who did not finish the intended number of cycles had an inferior TTF (45% vs 75% at 3 years; P 5 .005) 
Toxicity
Toxicity was evaluated for the 94 patients who started therapy. Thirty-five patients (37%) did not finish the planned number of chemotherapy cycles, and 32 of these 35 patients ended chemotherapy early because of toxicity after a median of 3 cycles (range, 1-7 cycles). The main reasons for not finishing the intended number of cycles of therapy included myelosuppression (24 patients), an infection (7 patients), a peripheral sensory neuropathy (1 patient), patient preference (1 patient), a secondary malignancy (1 patient), and loss to follow-up (1 patient). The most common toxic effects were hematologic, and they were most pronounced after the cytarabine-containing cycles (Table 4) . Four patients died of neutropenic sepsis, all after cycle 1 and with no correlation to age. Two variables were associated with hematologic toxicity that required dose reductions: an age > 65 years and treatment with the cytarabine-containing cycle (Table 5) . One patient developed myelodysplasia 4.5 years after receiving 8 cycles of therapy and died of it. From a total of 514 cycles, 154 cycles were associated with sensory peripheral neuropathies, including 134 (26%) at grade 1, 12 (2.3%) at grade 2, and 8 (1.6%) at grade 3 (Table 6 ).
DISCUSSION
In this phase 2, prospective, bi-institutional study, BzR-HCVAD alternating with BzR-MA without consolidation stem cell transplantation and without maintenance therapy resulted in high ORR and CR rates of 100% and 82%, respectively, in patients with aggressive, previously untreated MCL. The median TTF was 55 months after a median follow-up duration of 44 months, however, and this was similar to that reported for rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (R-hyperCVAD) alternating with rituximab, high-dose methotrexate, and high-dose cytarabine (R-MA) without bortezomib (56.4 months) 13 ; this suggests that the addition of bortezomib does not improve the outcome.
Several observations might explain the apparent lack of benefit. The percentage of patients with intermediate and high MIPI risk scores was higher in the current study (49% and 22% vs 30% and 17%, respectively), 15 and MIPI was a prognostic variable in the current study. In addition, 53% of the patients in the current study presented with a Ki-67 level 30%, whereas only 20% patients had a Ki-67 level 20% (the threshold used in a subsequent report of the 2005 study). 16 Such a retrospective comparison, however, carries limitations that could be addressed only in a randomized setting.
Another possible explanation is the lower dose intensity of bortezomib delivered in the current trial: only 2 Abbreviations: MIPI, Mantle Cell International Prognostic Index; OS, overall survival; TTF, time to treatment failure. a P <.05 was considered statistically significant.
doses of bortezomib were administered per cycle. Recent trials using 4 doses of bortezomib alone or in combination with less intense regimens showed a benefit with the addition of bortezomib. These regimens include bortezomib plus bendamustine and rituximab 17 ; bortezomib plus rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) 18 ; bortezomib plus cyclophosphamide, bortezomib, and dexamethasone 19 ; and the LYM3002 trial, a randomized, prospective trial of bortezomib combined with cyclophosphamide, doxorubicin, and prednisone (RCBHP) versus R-CHOP in elderly patients with newly diagnosed MCL or those not eligible for autologous stem cell transplantation. 20 The latter trial showed a significant improvement in the CR rate when bortezomib was included in the regimen (53% vs 42%; P 5 .007) and an improvement in the median progression-free survival (PFS; 25 vs 14 months; P 5 .001). At the time of its design (2006), our trial included only 2 doses of bortezomib per cycle because of concerns about neurotoxicity in cycle A when it was combined with vincristine and because of concerns about pulmonary toxicity in cycle B when it was combined with a cytarabine-containing regimen. This last one was reported in a leukemia trial 7 and in patients with multiple myeloma using single-agent bortezomib with a similar dose and schedule after prior intensive therapy and autoSCT. 21 On the other hand, the addition of only 2 doses of bortezomib per cycle to a modified RhyperCVAD regimen given every 28 days without methotrexate and cytarabine 22, 23 showed an improvement in 3-year PFS in comparison with historical controls (75% vs 50%). Other regimens using bortezomib with R-CHOP (days 1 and 4) followed by bortezomib as maintenance or consolidation have suggested a clinical benefit in comparison with historical controls. 24 One of the main differences in our trial in comparison with the regimens discussed previously is the administration of high doses of cytarabine, which in a large randomized phase 3 trial produced a higher rate of earlier CR, deeper responses (ie, molecular CR), and longer PFS. 25 Similarly, R-hyperCVAD alternating with R-MA produced a higher CR rate and longer PFS than R-CHOP. This difference might explain the lack of an additional benefit seen in the current trial when bortezomib was added to the intense regimen.
The question of the impact of schedule dependence on the bortezomib combination (ie, before or after cytotoxic exposure) remains unresolved, with varied conclusions in preclinical trials, and no clear best sequence has been identified through numerous combinations of bortezomib with chemoimmunotherapy regimens since our trial was designed; admittedly this issue becomes even more complex in the context of a multidrug regimen.
As has been reported in previous studies, an advanced age, a blastoid variant, a pretreatment b 2 -microglobulin serum level 3 mg/dL, a high proliferation index (Ki-67 level 50%), and a high MIPI risk score were all associated with a worse TTF and OS.
The frequency of grade 4 hematologic adverse events was greater than that reported in a similar regimen without bortezomib, 13 but this did not lead to an increased incidence of episodes of neutropenic fever or an increase in the number of dose reductions. In particular, the frequency of grade 3 or 4 peripheral neuropathies was low. Interestingly, only 1 of 94 evaluable patients had developed myelodysplasia as of the last follow-up. This result compares favorably with the 3 cases of myelodysplasia and 1 case of acute myelogenous leukemia reported previously with a similar median follow-up. 13 This lower frequency is also consistent with that reported by others. 26 Because of its particular myelotoxicity in patients older than 65 years, this intense therapy is not recommended for this age group outside clinical trials. Although additional follow-up is needed, a comparison with historical controls is difficult because newer drugs with unique mechanisms of action and significant activity are changing the landscape of MCL. Two agents already have been approved for the treatment of relapsed/ refractory MCL: lenalidomide [27] [28] [29] [30] [31] and ibrutinib are currently being tested as part of frontline therapeutic regimens. These drugs will offer strategies of either consolidation or maintenance after induction and will hopefully help continue to improve the duration of the initial response and the overall outcome.
In conclusion, the addition of bortezomib to RhyperCVAD alternating with R-MA did not improve TTF rates with the current dose and schedule tested. Because almost all the patients achieved CR, these results suggest that relapses are derived from minimal residual disease, which has clearly become a critical factor for the outcomes of patients with MCL and will likely become the next endpoint.
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